While this framework is developed based on KRASG12C‐mutant LUAD, it lays the groundwork for potentially challenging the ‘one‐size‐fits‐all’ paradigm in KRAS‐driven cancers, and may inform biomarker‐driven combinatorial therapies as well as guide future clinical trial design. The gene discussed is KRAS; the disease is cancer.